Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury

Journal of Vascular Surgery

Volumn 65, Issue 1, 2017, Pages 207-217.e3

  Wu, Bian ^a   Mottola, Giorgio ^a   Chatterjee, Anuran ^a   Lance, Kevin D ^a   Chen, Mian ^a   Siguenza, Iris O ^a   Desai, Tejal A ^a   Conte, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; KI 67 ANTIGEN; OMEGA 3 FATTY ACID; PLATELET DERIVED GROWTH FACTOR; POLOXAMER; POLYGLACTIN; RESOLVIN D1; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; AUTACOID; CARDIOVASCULAR AGENT; DOCOSAHEXAENOIC ACID; DRUG CARRIER; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; RELA PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL SMOOTH MUSCLE CELL; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; BIODEGRADABILITY; CAROTID ANGIOPLASTY; CELL MIGRATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOSKELETON; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; GEL; HISTOLOGY; IN VITRO STUDY; INFLAMMATION; MALE; MORPHOMETRICS; NEOINTIMA; NONHUMAN; OXIDATIVE STRESS; PERIVASCULAR DELIVERY; PRIORITY JOURNAL; PROTEIN INDUCTION; RAT; ADVERSE EFFECTS; ANIMAL; AORTA; CAROTID ARTERY DISEASES; CELL CULTURE; CELL MOTION; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG FORMULATION; HYPERPLASIA; METABOLISM; PATHOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; SMOOTH MUSCLE CELL; SPRAGUE DAWLEY RAT; TIME FACTOR; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, BALLOON; ANIMALS; AORTA; CARDIOVASCULAR AGENTS; CAROTID ARTERY DISEASES; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CYTOSKELETON; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; DRUG CARRIERS; DRUG COMPOUNDING; HYPERPLASIA; INFLAMMATION MEDIATORS; KI-67 ANTIGEN; LACTIC ACID; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; OXIDATIVE STRESS; POLOXAMER; POLYGLYCOLIC ACID; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TRANSCRIPTION FACTOR RELA;

EID: 84962275480     PISSN: 07415214     EISSN: 10976809     Source Type: Journal    
DOI: 10.1016/j.jvs.2016.01.030     Document Type: Conference Paper

References (35)

1. 1 Criqui, M.H., Peripheral arterial disease—epidemiological aspects. Vasc Med 6 (2001), 3–7.
2. 2 Hirsch, A.T., Hartman, L., Town, R.J., Virnig, B.A., National health care costs of peripheral arterial disease in the Medicare population. Vasc Med 13 (2008), 209–215.
3. 3 Mahoney, E.M., Wang, K., Cohen, D.J., Hirsch, A.T., Alberts, M.J., Eagle, K., et al. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes 1 (2008), 38–45.
4. 4 Bradbury, A.W., Adam, D.J., Bell, J., Forbes, J.F., Fowkes, F.G., Gillespie, I., et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: analysis of amputation free and overall survival by treatment received. J Vasc Surg 51 (2010), 18S–31S.
5. 5 Conte, M.S., Bandyk, D.F., Clowes, A.W., Moneta, G.L., Seely, L., Lorenz, T.J., et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 43 (2006), 742–751.
6. 6 Inoue, T., Croce, K., Morooka, T., Sakuma, M., Node, K., Simon, D.I., Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 4 (2011), 1057–1066.
7. 7 Serhan, C.N., Pro-resolving lipid mediators are leads for resolution physiology. Nature 510 (2014), 92–101.
8. 8 Merched, A.J., Ko, K., Gotlinger, K.H., Serhan, C.N., Chan, L., Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J 22 (2008), 3595–3606.
9. 9 Ho, K.J., Spite, M., Owens, C.D., Lancero, H., Kroemer, A.H., Pande, R., et al. Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol 177 (2010), 2116–2123.
10. 10 Chatterjee, A., Sharma, A., Chen, M., Toy, R., Mottola, G., Conte, M.S., The pro-resolving lipid mediator maresin 1 (MaR1) attenuates inflammatory signaling pathways in vascular smooth muscle and endothelial cells. Plos One 9 (2014), 1–11.
11. 11 Miyahara, T., Runge, S., Chatterjee, A., Chen, M., Mottola, G., Fitzgerald, J.M., et al. D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J 4 (2013), 1–13.
12. 12 Akagi, D., Chen, M., Toy, R., Chatterjee, A., Conte, M.S., Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice. FASEB J 29 (2015), 2504–2513.
13. 4 signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation. Int J Cardiol 20 (2015), 370–372.
14. 14 Signore, P.E., Machan, L.S., Jackson, J.K., Burt, H., Bromley, P., Wilson, J.E., et al. Complete inhibition of intimal hyperplasia by perivascular delivery of paclitaxel in balloon-injured rat carotid arteries. J Vasc Interv Radiol 12 (2001), 79–88.
15. 15 Kohler, T.R., Toleikis, P.M., Gravett, D.M., Avelar, R.L., Inhibition of neointimal hyperplasia in a sheep model of dialysis access failure with the bioabsorbable Vascular Wrap paclitaxel-eluting mesh. J Vasc Surg 45 (2007), 1028–1038.
16. 16 Sanders, W.G., Hogrebe, P.C., Grainger, D.W., Cheung, A.K., Terry, C.M., A biodegradable perivascular wrap for controlled, local and directed drug delivery. J Control Release 16 (2012), 81–89.
17. 17 Yu, X., Takayama, T., Goel, S.A., Shi, X., Zhou, Y., Kent, K.C., et al. A rapamycin-releasing perivascular polymeric sheath produces highly effective inhibition of intimal hyperplasia. J Control Release 191 (2014), 47–53.
18. 18 Kerimoglu, O., Alarcin, E., Poly(lactic-co-glycolic acid) based drug delivery devices for tissue engineering and regenerative medicine. ANKEM Derg 26 (2012), 86–98.
19. 19 Wang, G.J., Sui, X.X., Samosa, H.F., Jain, M.K., Altieri, D.C., Conte, M.S., Regulation of vein graft hyperplasia by survivin, an inhibitor of apoptosis protein. Arterioscler Thromb Vasc Biol 25 (2005), 2081–2087.
20. 20 Wessely, R., New drug-eluting stent concepts. Nat Rev Cardiol 7 (2010), 194–203.
21. 21 Ostrovsky, G., Angiotech suspends Vascular Wrap trial enrollment. Medgadget, 2008.
22. 22 Chiang, N., Fredman, G., Backhed, F., Oh, S.F., Vickery, B.A., Serhan, C.N., Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 484 (2012), 524–528.
23. 23 Spite, M., Norling, L., Summers, L., Yang, R., Cooper, D., Petasis, N.A., et al. Resolvin D2 is a potent regulation of leukocytes and controls microbial sepsis. Nature 461 (2009), 1287–1291.
24. 24 Krishnamoorthy, S., Recchiuti, A., Chiang, N., Yacoubian, S., Lee, C.H., Yang, R., et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A 107 (2010), 1660–1665.
25. 25 Ohira, T., Arita, M., Omori, K., Recchiuti, A., Van Dyke, T.E., Serhan, C.N., Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem 285 (2010), 3451–3461.
26. 26 Fullerton, J.N., O'Brien, A.L., Gilroy, D.W., Lipid mediators in immune dysfunction after severe inflammation. Trends Immunol 35 (2014), 12–21.
27. 27 Vavra, A.K., Havelka, G.E., Martinez, J., Lee, V.R., Fu, B., Jiang, Q., et al. Insights into the effect of nitric oxide and its metabolites nitrite and nitrate at inhibiting neointimal hyperplasia. Nitric Oxide 25 (2011), 22–30.
28. 28 Clowes, A.W., Schwartz, S.M., Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res 56 (1985), 139–145.
29. 29 Davies, M.G., Hagen, P.O., Pathobiology of intimal hyperplasia. Br J Surg 81 (1994), 1254–1269.
30. 30 Schwartz, S.M., Smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 99 (1997), 2814–2817.
31. 31 Muto, A., Model, L., Ziegler, K., Eghbalieh, S.D., Dardik, A., Mechanisms of vein graft adaptation to the arterial circulation: insights into the neointimal algorithm and management strategies. Circ J 74 (2010), 1501–1512.
32. 32 Autieri, M.V., Yue, T.L., Ferstein, G.Z., Ohlstein, E., Antisense oligonucleotides to the p65 subunit of NF-κB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointimal formation in rat carotid arteries. Biochem Biophys Res Commun 213 (1995), 827–835.
33. 33 Zahradka, P., Werner, J.P., Buhay, S., Litchie, B., Helwer, G., Thomas, S., NF-κB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells. J Mol Cell Cardiol 34 (2002), 1609–1621.
34. 34 Finkel, T., Oxygen radicals and signaling. Curr Opin Cell Biol 10 (1998), 248–253.
35. 35 Almeida, H., Amaral, M.H., Lobao, P., Lobo, J.M., Pluronic F-127 and Pluronic Lecithin Organogel (PLO): main features and their applications in topical and transdermal administration of drugs. J Pharm Pharm Sci 15 (2012), 592–605.